ClinicalTrials.gg
CompletedNCT05238493Updated Jun 27, 2024

A Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VEL-101

A Phase 1 interventional study of VEL-101 and Placebo in Healthy Volunteers, sponsored by Veloxis Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-27.

Sponsored by Veloxis Pharmaceuticals · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Jan 2023, 3 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study is primarily designed to assess the safety and tolerability of single doses of VEL-101 when administered subcutaneously (via injection into an area under the skin) or intravenously (via infusion into a vein). As each new group of participants is enrolled into the study, the dose administered to that group may be higher than a previous dose shown to be safe in other participants. The study is also designed to determine blood levels of VEL-101 and some substances produced by the immune system following VEL-101 administration. This information can provide insight into how quickly VEL-101 is eliminated from the body and some if its effects on the body.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Veloxis Pharmaceuticals is the lead sponsor of 18 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to understand the key components of the study as described in the written document, and willing and able to provide written informed consent;
  2. Self-described healthy male or female, 18 to 65 years of age, inclusive, at Screening;
  3. (BMI) within the range of 18.5 to \<35 kg/m2 at Screening;
  4. If female, is surgically sterile, 2 years , or, if of , is using a medically accepted method of (abstinence, the simultaneous use of 2 barrier methods, or the use of an intrauterine device [in place at least 3 months prior to dosing], or oral contraceptives), and agrees to continued use of this method until study Day 50;
  5. If male, agrees to use an approved method of contraception (abstinence, 2 barrier methods, female partner's use of an intrauterine device [in place at least 3 months prior to dosing], oral contraceptives or female partner who is surgically sterile or 2 years postmenopausal) and agrees to use this method until study Day 50;
  6. Able to comply with all study procedures, including the required overnight stays in the clinical research center and the food, beverage, and medication restrictions during the study;
  7. In the opinion of the Investigator, is able to adhere to the requirements of the study.

Exclusion criteria

Exclusion Criteria:

  1. Known allergy to study medication or its components (non-medicinal ingredients) or a history of a severe allergic reaction to any drug or history of multiple food/drug allergies;
  2. Use of tobacco, smoking cessation products, or products containing nicotine within 3 months prior to Screening;
  3. History of alcohol or illicit drug use disorder, marijuana consumption as defined in the , 5th edition, or a reported habitual alcohol intake greater than 1.5 oz (ethanol equivalent) per day (eg, 24 oz of beer, 10 oz of wine, or 3 oz of hard liquor) for the past two years;
  4. Positive urine screen for drugs of abuse including tetrahydrocannabinol or has a positive breathalyzer test on admission to the study center, at Screening and at Baseline for each treatment cohort;
  5. Positive serologic test for surface antigen (HBsAg), hepatitis B core antibody (HBcAb), virus (HCV) antibody, (HIV), or positive for EBV polymerase chain reaction [PCR] at Screening;
  6. Negative for Epstein-Barr Virus ([EBV], viral capsid antigen [VCA IgG], Epstein-Barr nuclear antigen antibody [EBNA],);
  7. History of inadequately treated active or latent mycobacterium tuberculosis (TB) infection or positive QuantiFERON® TB Gold at Screening;
  8. History of diabetes, cardiovascular, pulmonary, hepatic, renal, or malabsorptive disease, as determined by the Principal Investigator (PI);
  9. Clinically significant abnormality upon physical examination at Screening, as determined by the Investigator;
  10. Clinically significant abnormality on 12-lead at Screening, as determined by the Investigator;
  11. Clinically significant abnormal laboratory values (clinical chemistry, hematology, coagulation, or urinalysis) outside the reference values established by the laboratory, as determined by the Investigator at Screening;
  12. Positive pregnancy test or lactating at Screening or at Day -1;
  13. Participation in an study within 30 days or within 5 half-lives of the investigational drug, whichever is longer, prior to the Screening Visit;
  14. Receiving any antibody or biologic medicinal product within 90 days prior to Screening;
  15. Blood or plasma donation within 72 hours prior to Screening or planned up to study Day 50;
  16. Positive test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen testing or equivalent testing on Day -1; Subjects fully recovered from coronavirus disease 2019 (COVID-19) infection are eligible. Subjects with a past history of hospitalization due to COVID-19 infection will be excluded;
  17. History of infection or vaccination within 90 days prior to the Screening, or planned vaccination within 90 days of dosing, with the exception of vaccination against SARS CoV-2;
  18. History or presence, upon clinical evaluation, of any illness that, in the opinion of the Investigator, would interfere with the ability to provide or comply with study instructions, or that might confound the interpretation of the study results or put the subject at undue risk.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Subcutaneous (SQ) Dose "A"

    Single dose of VEL-101 by SQ injection

    Drug: VEL-101

  • Experimental
    Intravenous (IV) Dose "A"

    Single dose of VEL-101 by IV infusion

    Drug: VEL-101

  • Experimental
    SQ Dose "B"

    Single dose of VEL-101 by SQ injection

    Drug: VEL-101

  • Experimental
    SQ Dose "C"

    Single dose of VEL-101 by SQ injection

    Drug: VEL-101

  • Experimental
    IV Dose "C"

    Single dose of VEL-101 by IV infusion

    Drug: VEL-101

  • Experimental
    SQ Dose "D"

    Single dose of VEL-101 by SQ injection

    Drug: VEL-101

  • Experimental
    SQ Dose "E"

    Single dose of VEL-101 by SQ injection

    Drug: VEL-101

  • Placebo comparator
    SQ or IV Placebo

    Single dose of Placebo by SQ injection or IV infusion

    Drug: Placebo

Interventions

  • Intervention administered via subcutaneous injection or 1-hour intravenous infusion on Day 1

  • DrugPlacebo

    Intervention administered via subcutaneous injection or 1-hour intravenous infusion on Day 1

06

What researchers measure

Primary outcomes

  1. Number and Percentage of Participants with Treatment-emergent Adverse Events (TEAEs)

    Number and percentage of participants experiencing one or more adverse events which occurred or worsened in severity after initiation of investigational product (IP) dosing

    Time frame: Day 1 through Day 50

  2. Number and Percentage of Participants with Serious TEAEs

    Number and percentage of participants experiencing one or more serious TEAEs

    Time frame: Day 1 through Day 50

  3. Number and Percentage of Participants with Grade 3 or Higher TEAEs

    Number and percentage of participants experiencing one or more grade 3 TEAEs

    Time frame: Day 1 through Day 50

  4. Number and Percentage of Participants with TEAEs Leading to Withdrawal from the Study

    Number of participants experiencing one or more TEAEs directly resulting in withdrawal from the study

    Time frame: Day 1 through Day 50

  5. Number and Percentage of Participants with TEAEs Leading to Death

    Number and percentage of participants experiencing TEAEs that resulted in death

    Time frame: Day 1 through Day 50

Secondary outcomes

  1. Number and Percentage of Participants with Abnormal Chemistry Panel Results

    Descriptive statistics will summarize results (including change from baseline, as appropriate) of the following at each time point: sodium, potassium, chloride, calcium, bicarbonate, glucose, phosphorus, blood urea nitrogen, creatinine, creatine kinase, C-reactive protein, estimated glomerular filtration rate (eGFR), magnesium, amylase, uric acid, alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), albumin, alkaline phosphatase, direct bilirubin, total bilirubin, indirect bilirubin, total protein, and lactate dehydrogenase

    Time frame: Days -1, 2 (24 hours), 3, 5, 8, 15, 22, 29, 50

  2. Number and Percentage of Participants with Abnormal Hematology Panel Results

    Descriptive statistics will summarize results (including change from baseline, as appropriate) of the following at each time point: hematocrit, hemoglobin, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), red cell distribution width (RDW), red blood cells (RBC), white blood cells (WBC) and differential, and platelets

    Time frame: Days -1, 2 (24 hours), 3, 5, 8, 15, 22, 29, 50

  3. Number and Percentage of Participants with Abnormal Coagulation Panel Results

    Descriptive statistics will summarize results (including change from baseline, as appropriate) of the following at each time point: prothrombin time (PT), international normalized ratio (INR), partial thromboplastin time (PTT), and fibrinogen

    Time frame: Days -1, 2 (24 hours), 3, 5, 8, 15, 22, 29, 50

  4. Number and Percentage of Participants with Abnormal Urinalysis Results

    Descriptive statistics will summarize results (including change from baseline, as appropriate) of the following at each time point: specific gravity, pH, leukocytes, erythrocytes, protein, glucose, nitrite, urobilinogen, bilirubin, ketones, and additional microscopic examination if blood or protein are abnormal

    Time frame: Days -1, 2 (24 hours), 3, 5, 8, 15, 22, 29, 50

  5. Number and Percentage of Participants with Abnormal 12-lead Electrocardiogram (ECG) Results

    Descriptive statistics will summarize results (including change from baseline, as appropriate) of the following at each time point: PR interval, QRS duration, QT interval, corrected QT interval (QTc), and corrected QT interval using Fridericia's formula (QTcF)

    Time frame: Days 1 (0, 1, 2, 3, 4, 5, 8, 12, 12, 16, and 20 hours), 2 (24, 30, 36, and 42 hours), 3, 4, 5, 8, 29, 50

  6. Number and Percentage of Participants with Abnormal Vital Signs Results

    Descriptive statistics will summarize results (including change from baseline, as appropriate) of the following at each time point: heart rate (HR), respiratory rate (RR), blood pressure (BP), temperature, and oxygen saturation

    Time frame: Days -1, 1 (0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 8, 12, 16, 20 hours), 2 (24, 30, 36, 42 hours), 3, 4, 5, 6, 7, 8, 15, 22, 29, 50

  7. CD28 Receptor Occupancy

    Proportion of target receptors occupied by VEL-101

    Time frame: Day 1 (0, 1, 3, 5, 8 hours) and Days 2 (24 hours), 3, 15, 22, 29, 50

  8. Number and Percentage of Participants with Anti-drug Antibody (ADA) Formation

    Presence of detectable anti-VEL-101 antibodies; neutralizing antibody assessments to be performed in samples positive for ADA

    Time frame: Days 1 (0 hour), 15, 29, 50

  9. Number and Percentage of Participants with Detectable Systemic Cytokine Concentrations

    Interferon-gamma, interleukin-1 beta, interleukin-2, interleukin-4, interleukin-5, interleukin-6, interleukin-8, interleukin-10, interleukin-13, interleukin-17, interleukin-12 p70 (heterodimer composed of p40 and p35 subunits), tumor necrosis factor-alpha

    Time frame: Day 1 (0, 1, 3, 5, 8 hours) and Days 2 (24 hours), 3, 15, 50

  10. Maximum Plasma Concentration (Cmax)

    The observed maximum plasma concentration

    Time frame: Day 1 (0, 1, 3, 5, 8 hours) and Days 2 (24 hours), 3, 4, 5, 6, 7, 8, 15, 22, 29, 50

  11. Time of Observed Maximum Plasma Concentration (Tmax)

    Time at which the observed maximum plasma concentration occurred

    Time frame: Day 1 (0, 1, 3, 5, 8 hours) and Days 2 (24 hours), 3, 4, 5, 6, 7, 8, 15, 22, 29, 50

  12. Terminal Elimination Rate Constant

    Terminal elimination rate constant, determined using the linear least squares regression of the terminal phase of the log plasma concentration time profile

    Time frame: Day 1 (0, 1, 3, 5, 8 hours) and Days 2 (24 hours), 3, 4, 5, 6, 7, 8, 15, 22, 29, 50

  13. Terminal Elimination Half-life

    Elimination half-life calculated using terminal phase plasma concentration data

    Time frame: Day 1 (0, 1, 3, 5, 8 hours) and Days 2 (24 hours), 3, 4, 5, 6, 7, 8, 15, 22, 29, 50

  14. Area Under the Plasma Concentration Versus Time Curve (AUC) from Time Zero to Time of Last Observed Quantifiable Concentration

    Area under the plasma concentration versus time curve (AUC) from time zero to time of last observed quantifiable concentration (different from AUC from time zero to infinity)

    Time frame: Day 1 (0, 1, 3, 5, 8 hours) and Days 2 (24 hours), 3, 4, 5, 6, 7, 8, 15, 22, 29, 50

  15. AUC from Time Zero to Infinity

    Area under the plasma concentration versus time curve from time zero to infinity

    Time frame: Day 1 (0, 1, 3, 5, 8 hours) and Days 2 (24 hours), 3, 4, 5, 6, 7, 8, 15, 22, 29, 50

  16. Total Clearance (CL)

    Total clearance from plasma

    Time frame: Day 1 (0, 1, 3, 5, 8 hours) and Days 2 (24 hours), 3, 4, 5, 6, 7, 8, 15, 22, 29, 50

  17. Terminal Volume of Distribution (Vz)

    Apparent volume of distribution in the terminal phase

    Time frame: Day 1 (0, 1, 3, 5, 8 hours) and Days 2 (24 hours), 3, 4, 5, 6, 7, 8, 15, 22, 29, 50

  18. Bioavailability (F)

    Absolute bioavailability

    Time frame: Day 1 (0, 1, 3, 5, 8 hours) and Days 2 (24 hours), 3, 4, 5, 6, 7, 8, 15, 22, 29, 50

07

Study locations

1 site
  • CTI Clinical Research Center
    Cincinnati, Ohio 45212, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2022 to primary completion in Jan 2023, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2022
First posted
Feb 14, 2022
StartActual
Apr 26, 2022
Primary completionActual
Jan 3, 2023
CompletionActual
Jan 3, 2023
Last update
Jun 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05238493
Lead sponsor
Veloxis Pharmaceuticals
Responsible party
Sponsor
First posted
Feb 14, 2022
Start date
Apr 26, 2022
Primary completion
Jan 3, 2023
Completion
Jan 3, 2023
Last update
Jun 27, 2024

Study contacts

Libbie McKenzie, MD
study director · Veloxis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegrizeprument

Start the discussion